Targeted protein degraders: a call for collective action to advance safety assessment

被引：14

作者：

Jones, Lyn H. ^{[1
]}

Mitchell, Constance A. ^{[2
]}

Loberg, Lise ^{[3
]}

Pavkovic, Mira ^{[4
]}

Rao, Mohan ^{[5
]}

Roberts, Ruth ^{[6
,7
]}

Stamp, Katie ^{[8
]}

Volak, Laurie ^{[5
]}

Wittwer, Matthias B. ^{[9
]}

Pettit, Syril ^{[2
]}

机构：

[1] Dana Farber Canc Inst, Ctr Prot Degradat, Boston, MA 02115 USA

[2] Hlth & Environm Sci Inst, Washington, DC 17602 USA

[3] AbbVie, N Chicago, IL 60064 USA

[4] Bayer, Wuppertal, Germany

[5] Janssen Pharmaceut Companies Johnson & Johnson, San Diego, CA USA

[6] ApconiX, Alderley Edge, England

[7] Univ Birmingham, Dept Biosci, Birmingham, W Midlands, England

[8] Bristol Myers Squibb, New York, NY USA

[9] F Hoffmann La Roche, Roche Innovat Ctr Basel, Basel, Switzerland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 06期

关键词：

D O I：

10.1038/d41573-022-00055-9

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Targeted protein degraders (TPDs) are emerging classes of therapeutics that have the potential to address difficult drug targets in new ways. In 2021, experts convened to discuss challenges in TPD safety evaluation, and supported supplementing individual efforts to address these challenges with collective development of novel decision frameworks, tools and a shared evidence base. Targeted protein degraders (TPDs) are emerging classes of therapeutics that have the potential to address difficult drug targets in new ways. In 2021, experts convened to discuss challenges in TPD safety evaluation, and supported supplementing individual efforts to address these challenges with collective development of novel decision frameworks, tools and a shared evidence base.

引用

页码：401 / 402

页数：2

共 50 条

[1] Targeted protein degraders: a call for collective action to advance safety assessment
Lyn H. Jones
Constance A. Mitchell
Lise Loberg
Mira Pavkovic
Mohan Rao
Ruth Roberts
Katie Stamp
Laurie Volak
Matthias B. Wittwer
Syril Pettit
Nature Reviews Drug Discovery, 2022, 21 : 401 - 402
[2] Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
Loberg, Lise I.
Proctor, William R.
Burdick, Andrew D.
Cauvin, Annick
Delise, Anthony M.
Hemkens, Michelle
Hohlbaum, Andreas M.
Hukkanen, Renee
Sedgwick, Alanna E.
Shuey, Dana
Zane, Doris T.
Stamp, Katie
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2025, 158
[3] Monomeric Targeted Protein Degraders
Hanan, Emily J.
Liang, Jun
Wang, Xiaojing
Blake, Robert A.
Blaquiere, Nicole
Staben, Steven T.
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (20) : 11330 - 11361
[4] Proteolytic platelets as targeted protein degraders
Chen, Yu
Hu, Quanyin
NATURE BIOTECHNOLOGY, 2024,
[5] CNS delivery of targeted protein degraders
Agarwal, Prashant
Reid, Darren L.
Amiji, Mansoor
JOURNAL OF CONTROLLED RELEASE, 2024, 372 : 661 - 673
[6] Targeted protein degraders crowd into the clinic
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (04) : 247 - 250
[7] Targeted protein degraders crowd into the clinic
Asher Mullard
Nature Reviews Drug Discovery, 2021, 20 : 247 - 250
[8] Clinical Translation of Targeted Protein Degraders
Kong, Nikki R.
Jones, Lyn H.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (03) : 558 - 568
[9] Targeted protein degradation and the enzymology of degraders
Fisher, Stewart L.
Phillips, Andrew J.
CURRENT OPINION IN CHEMICAL BIOLOGY, 2018, 44 : 47 - 55
[10] Targeted degraders clear first safety hurdles
Asher Mullard
Nature Reviews Drug Discovery, 2020, 19 (7) : 435 - 435

← 1 2 3 4 5 →